Japanese drugmaker Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been launched in the company’s home country for the ...

Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer: Tokyo Thursday, March 20, 2025, ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

Cambridge, USA-based clinical-stage oncology company Immuneering (Nasdaq: IMRX) announced the appointment of Dr Igor ...

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...

Joseph Mossel is the CEO of Ibex Medical Analytics. His career in the tech industry spans more than 20 years, starting off in ...

The Japanese government did not approve a visit by former Taiwan President Tsai Ing-wen last July to attend a memorial ...

On March 11, 2025, we remember the profound loss and resilience of the people of Japan following the Great East Japan ...

Thanks to the spending growth cap, the U.K. government in December 2024 announced that companies would need to pay a 22.9% ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...